INTRODUCTION

IPF is one of the most deadly ILDs1

It can be more deadly than many cancers2,3


5-year survival rate in IPF vs types of cancer2

IPF has a lower 5-year survival rate than colon cancer, female breast cancer, and prostate cancer
IPF Claims
~40,000
US LIVES EVERY YEAR-AS MANY AS BREAST CANCER4,5
3-5 YEARS MEDIAN SURVIVAL1
By definition, IPF is an ILD that is
always progressive6

ILDs with progressive pulmonary fibrosis behave in a clinically similar way to IPF7,8

Lung function decline

Lung function decline

Worsening respiratory symptoms

Worsening respiratory symptoms

Worsening quality of life

Worsening quality of life

Early mortality

Early mortality

Signs of disease progression in patients with fibrotic ILD may include9,10:

  • Physician or patient impression that disease has worsened
  • Decrease in exercise capacity
  • Decline in FVC and/or DLCO on PFTs
  • Worsening cough or dyspnea
  • Acute exacerbations
  • Increasing fibrosis on HRCT

Percentage of patients with non-IPF ILDs who may develop progressive pulmonary fibrosis11,*

*According to an online survery of physicians

18 to 32 percent of patients with ILD may develop progressive pulmonary fibrosis

Progressive pulmonary fibrosis in ILDs can be deadly12–22

Low survival time (years) for progressive pulmonary fibrosis in ILDs

Pulmonary fibrosis causes irreversible lung damage23

Pulmonary fibrosis scars and stiffens tissue, making it harder to breathe.23-25

Lungs with distorted architecture, fibrosis, and impaired gas exchange

Impact on quality of life29:

  • Worsening dyspnea and cough
  • Limited ability to perform day-to-day activities
  • Strain on emotional well-being
Fibrosis, or scarring, is chronic and irreversible, making early recognition and referral critical in ILD1,23,24
video

Progressive Fibrosing ILD Video

References:
1. Oldham JM, Noth I. Respir Med. 2014;108(6):819-829. 2. Vancheri C et al. Eur Respir J. 2010;35:496-504. 3. Fujimoto H et al. Clin Med Insights. 2015;9(S1):179-185. 4. National Institutes of Health. ARRA impact report: functional genomics of lung diseases. https://report.nih.gov/recovery/impactreports/PrintPage.aspx?Id=14. Accessed June 1, 2022. 5. US Cancer Statistics Working Group. United States Cancer Statistics: 1999–2012 Incidence and Mortality Web-based Report. (http://nccd.cdc.gov/uscs/) Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2015. 6. Cottin V et al. Eur Respir Rev. 2019;28(153):190109. 7. Wells AU et al. Eur Respir J. 2018;51(5):1800692. 8. Cottin V et al. Eur Respir Rev. 2018;27(150):180076. 9. Kolb M, Vašáková M. Respir Res. 2019:20(1):57. 10. Wong AW et al. Respir Res. 2020;21(1):323. 11. Wijsenbeek M et al. Curr Med Res Opin. 2019;35(11):2015-2024. 12. Ryerson CJ et al. Eur Respir J. 2013;42:750-757. 13. Hyldgaard C et al. Respirology. 2017;22(3):494-500. 14. Wells AU et al. Am J Respir Crit Med. 1994;149(6):1583-1590. 15. Mapel DW. Thorax. 1998;53(6):469-476. 16. Hubbard R et al. Chest. 1998;113(2):396-400. 17. Goh NS et al. Am J Respir Crit Care Med. 2008;177(11):1248-1254. 18. Moore OA et al. Rheumatology. 2013;52(1):155-160. 19. Kim EJ et al. Eur Respir J. 2010;35(6):1322-1328. 20. Bongartz T et al. Arthritis Rheum. 2010;62(6):1583-1591. 21. Gimenez A et al. Thorax. 2018;73(4):391-392. 22. Vourlekis JS et al. Am J Med. 2004;116(10):662-668. 23. Wollin L et al. Eur Respir J. 2019;54(3):1900161. 24. Selman M et al. Ann Intern Med. 2001;134(2):136-151. 25. Tonelli R et al. BMC Pulm Med. 2017;17(1):130. 26. Wells AU, Denton CP. Nat Rev Rheumatol. 2014;10(12):728-739. 27. Bagnato G, Harari S. Eur Respir Rev. 2015;24(135):102-114. 28. Kolb M, Vašáková M. Respir Res. 2019;20(1):57. 29. Swigris JJ et al. Eur Respir Rev. 2018;27(150):180075.

red arrow red arrow